在类风湿性关节炎中,阿达利穆马布度,抗药抗体和疾病活性之间的关系:一项横截面观察性研究
Lisa K Stamp1, Paula Keating2, Christopher Frampton3
1L.K. Stamp, MBChB, PhD, C. Frampton, PhD, M.L. Barclay, MBChB, N. Fanning, PhD, Department of Medicine, University of Otago Christchurch, Christchurch; Lisa.Stamp@cdhb.health.nz.
The Journal of rheumatology
|January 15, 2024
概括
在类风湿性关节炎患者中,较高的阿达利穆马布 (ADA) 度与较低的炎症标志物如C反应蛋白和IL-6相关. 5-7毫克/升之间的最佳ADA水平与更好的疾病控制有关.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 药理动力学 药理动力学
背景情况:
- 类风湿性关节炎 (RA) 管理通常涉及生物疗法,如阿达利穆马布 (ADA).
- 了解影响ADA度的因素对于优化治疗疗效至关重要.
- 患者的特征和疾病活动可以影响治疗药物水平.
研究的目的:
- 研究患者因素和疾病活动如何影响RA患者的ADA度.
- 检查ADA水平,抗药抗体 (ADAb) 和疾病控制之间的关系.
- 探索细胞因子水平和ADA度之间的关联.
主要方法:
- 一项横截面研究包括156名RA患者在ADA上治疗≥4周.
- 用28个关节的疾病活动评分 (DAS28) 测量疾病活动.
- 分析了血清/血ADA,ADAb和细胞因子水平;通过ANOVA和一般线性模型评估了相关性.
主要成果:
- 较高的C-反应蛋白和体重独立地与较低的ADA度有关.
- 与DAS28>3.2的患者相比,DAS28 ≤3.2的患者 (响应者) 的ADA水平显著更高.
- 在介质素-6 (IL-6) 和ADA度之间观察到负相关性.
结论:
- 在RA中,ADA度与炎症标记物,包括IL-6相反相关.
- 从5至7毫克/升的治疗性ADA度与改善的疾病控制有关.
- 监测ADA水平可能有助于个性化RA治疗策略.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
139
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
139
Affinity and Avidity
36.1K
Overview
36.1K
Quantitative Aspects of Drug-Receptor Interaction
985
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
985
Structure-Activity Relationships and Drug Design
726
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
726
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Rational Dosage Regimen: Maintenance Dose and Loading Dose
4.1K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.1K


